2025
SJR Q1
JCR Q2 · 3,5
60 eşleşen makale
SCIE
Dergi ayrıntısı
Cardiovascular Drugs and Therapy
- Yayıncı
- Springer
- Ülke
- United States · Northern America
- Tür
- journal
- ISSN
-
0920320615737241
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 1,016
- Quartile Q1
- H-Index 85
- Atıf/yayın 3,27
- Doküman (3y) 377
- Atıf (3y) 1.225
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 3,5
- 5Y JIF 3,7
- JCI 0,78
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Cardiology and Cardiovascular Medicine Q1
- Medicine (miscellaneous) Q1
- Pharmacology Q1
- Pharmacology (medical) Q1
Alanlar
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS kategorileri
- Cardiac & Cardiovascular System | Pharmacology & Pharmacy
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q2 | 1,016 | 3,5 | 3,7 | 0,78 | Q2 | 85 |
| 2024 | Q1 | Q2 | 1,002 | 3,1 | 3,3 | 0,78 | Q2 | 83 |
| 2023 | Q1 | Q2 | 0,973 | 3,1 | 3,3 | 0,8 | Q2 | 83 |
| 2022 | Q1 | Q2 | 0,913 | 3,4 | 3,8 | 0,77 | Q2 | 83 |
| 2021 | Q1 | Q2 | 0,86 | 3,9 | 4,5 | 0,85 | Q2 | 83 |
| 2020 | Q1 | Q2 | 1,108 | 3,7 | 4,1 | 1,04 | Q1 | 83 |
| 2019 | Q1 | Q1 | 1,36 | 4,1 | 3,2 | 1,03 | Q1 | 83 |
| 2018 | — | Q1 | — | 4,2 | 3,4 | 1,05 | Q1 | — |
| 2017 | Q1 | Q2 | 1,349 | 2,8 | 2,8 | 0,83 | Q2 | 83 |
| 2016 | Q1 | Q2 | 1,067 | 2,8 | 2,8 | — | — | 83 |
| 2015 | Q1 | Q2 | 1,238 | 3,2 | 2,9 | — | — | 83 |
| 2014 | Q1 | Q2 | 1,222 | 3,2 | 3 | — | — | 83 |
| 2013 | Q1 | Q2 | 1,016 | 3 | 2,6 | — | — | 83 |
| 2012 | Q1 | Q2 | 1,196 | 2,7 | 2,8 | — | — | 83 |
| 2011 | Q1 | Q2 | 1,016 | 3,1 | 2,6 | — | — | 83 |
| 2010 | Q1 | Q2 | 1,289 | 3,1 | 2,7 | — | — | 83 |
| 2009 | — | Q2 | — | 2,5 | 2,3 | — | — | — |
| 2008 | — | Q2 | — | 2,5 | 2,2 | — | — | — |
| 2007 | — | Q2 | — | 1,9 | 1,9 | — | — | — |
| 2006 | — | Q3 | — | 1,4 | — | — | — | — |
| 2005 | — | Q2 | — | 1,6 | — | — | — | — |
| 2004 | — | Q3 | — | 1,5 | — | — | — | — |
| 2003 | — | Q3 | — | 1,1 | — | — | — | — |
| 2002 | — | Q3 | — | 0,9 | — | — | — | — |
| 2001 | — | Q3 | — | 1 | — | — | — | — |
| 2000 | — | Q3 | — | 1 | — | — | — | — |
| 1999 | — | Q2 | — | 1,1 | — | — | — | — |
| 1998 | — | Q2 | — | 1,1 | — | — | — | — |
| 1997 | — | Q2 | — | 1,1 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q2 | 72/237 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 134/356 |
| 2024 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q2 | 70/231 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 134/352 |
| 2023 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q2 | 68/222 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 126/354 |
| 2022 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q2 | 63/143 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 125/278 |
| 2021 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q2 | 64/143 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 117/279 |
| 2020 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q1 | 61/142 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 126/276 |
| 2019 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q1 | 37/138 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 60/271 |
| 2018 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q1 | 38/136 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 47/267 |
| 2017 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q2 | 56/128 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 111/261 |
| 2016 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 53/126 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 102/257 |
| 2015 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 42/124 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 69/255 |
| 2014 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 42/123 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 71/255 |
| 2013 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 47/125 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 80/256 |
| 2012 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 48/124 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 99/261 |
| 2011 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 38/117 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 70/261 |
| 2010 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 39/114 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 72/252 |
| 2009 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 39/95 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 106/237 |
| 2008 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 29/79 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 98/219 |
| 2007 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 37/75 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 117/205 |
| 2006 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | — | 43/74 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 135/199 |
| 2005 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 35/72 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 112/193 |
| 2004 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | — | 37/71 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 111/187 |
| 2003 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | — | 40/70 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 129/185 |
| 2002 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | — | 46/66 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 136/188 |
| 2001 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | — | 38/65 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 122/186 |
| 2000 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | — | 37/63 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 118/181 |
| 1999 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 28/67 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 93/175 |
| 1998 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 25/62 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 87/178 |
| 1997 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 25/62 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 88/157 |